Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis

American Journal of Medicine

Volumn 106, Issue 1, 1999, Pages 118-119

  Khurana, Vikas ^a   De La Fuente, Maria ^a   Bradley, Thomas P ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; PHENYLPROPANOLAMINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG POTENTIATION; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

EID: 0033023618     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00370-2     Document Type: Article

References (4)

1. Benet L., Oie S., Schwartz J. Clemastine. Goodman L., Gilman A. Goodman and Gilman's Pharmacological Basis of Therapeutics. 1996;McGraw-Hill, New York.
2. Lake C.R., Gallant S., Mason E., Miller P. Adverse drug effects attributed to phenylpropanolamine a review of 142 case reports . Am J Med. 89:1990;195-208.
3. Conant M., Okabe M., Slaton A., et al. Stavudine (d4T) therapy one large clinic's experience . (Abstract.) Int Conf AIDS. 10:1994;7.
4. Adler M.H., Anderson R.E., Rutkiewicz V., et al. Clinical course of long term therapy with stavudine (d4T). (Abstract.) Intersci Conf Antimicrob Agents Chemother. 218:1994.